兴奋剂
化学
亚甲基
体内
咪唑
部分激动剂
立体化学
体外
药理学
受体
脚手架
衍生工具(金融)
小分子
组合化学
生物化学
医学
生物
药物化学
经济
生物技术
生物医学工程
金融经济学
作者
Mathias Hallberg,Colin Sumners,U. Muscha Steckelings,Anders Hallberg
摘要
Abstract The discovery of the first selective, small‐molecule ATR receptor (AT2R) agonist compound 21 (C21) ( 8 ) that is now extensively studied in a large variety of in vitro and in vivo models is described. The sulfonylcarbamate derivative 8 , encompassing a phenylthiofen scaffold is the drug‐like agonist with the highest affinity for the AT2R reported to date ( K i = 0.4 nM). Structure‐activity relationships (SAR), regarding different biaryl scaffolds and functional groups attached to these scaffolds and with a particular focus on the impact of various para substituents displacing the methylene imidazole group of 8 , are discussed. Furthermore, the consequences of migration of the methylene imidazole group and presumed structural requirements for ligands that are aimed as AT2R agonists (e.g. 8 ) or AT2R antagonists (e.g. 9 ), respectively, are briefly addressed. A summary of the pharmacological actions of C21 ( 8 ) is also presented.
科研通智能强力驱动
Strongly Powered by AbleSci AI